Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Paradigm Biopharmaceuticals Ltd. ( (AU:PAR) ) just unveiled an announcement.
Paradigm Biopharmaceuticals Ltd. announced its participation in the NWR Virtual Healthcare Conference, where Chief Medical Officer Dr. Donna Skerrett will present. This engagement underscores Paradigm’s commitment to addressing unmet medical needs and highlights its strategic efforts to enhance visibility and stakeholder engagement in the healthcare sector.
More about Paradigm Biopharmaceuticals Ltd.
Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on improving patient health and quality of life through pharmaceutical therapies. The company specializes in developing injectable pentosan polysulfate sodium (iPPS) for treating diseases with inflammatory pathogenesis, leveraging its anti-inflammatory and chondroprotective properties.
YTD Price Performance: 6.30%
Average Trading Volume: 8,346
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $103.6M
See more data about PAR stock on TipRanks’ Stock Analysis page.